Valuation: Voyageur Pharmaceuticals Ltd.

Market Cap 31.69M 22.62M 19.77M 18.24M 16.81M 2.18B 32.39M 218M 85.75M 1.07B 84.94M 83.08M 3.67B P/E 2024
-5.24x
P/E 2025 -7.5x
Enterprise Value 31.46M 22.45M 19.62M 18.11M 16.69M 2.16B 32.16M 216M 85.12M 1.06B 84.32M 82.47M 3.65B EV / Sales 2024
-
EV / Sales 2025 2,423,581,172x
Free-Float
93.07%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer - 2019-06-30
Director of Finance/CFO - 2022-08-16
Chief Tech/Sci/R&D Officer - 2024-09-16
Director TitleAgeSince
Director/Board Member 62 -
Director/Board Member - 2017-12-05
Director/Board Member - 2019-06-30
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+7.14% - - 22.62M
+0.85%-0.80%+52.79%+161.33% 1,051B
+1.23%-1.53%+54.58%+59.08% 609B
+0.04%+2.58%+34.47%+86.33% 450B
+0.78%-0.71%+29.28%+24.10% 330B
+1.41%+0.58%+35.44%+40.67% 284B
-0.27%-1.87%+22.34%+22.51% 263B
-1.76%+2.37%-20.43%-38.00% 223B
-1.42%+0.80%+24.27%+57.50% 198B
-1.48%+3.43%+24.08%+71.67% 167B
Average -0.06%+0.54%+28.54%+53.91% 397.23B
Weighted average by Cap. +0.37%+0.02%+37.51%+79.63%

Financials

2024 2025
Net sales - 0.01 0.01 0.01 0.01 0.01 0.8 0.01 0.08 0.03 0.39 0.03 0.03 1.35
Net income -1.71M -1.22M -1.06M -983K -906K -117M -1.75M -11.75M -4.62M -57.47M -4.58M -4.48M -198M -3.53M -2.52M -2.2M -2.03M -1.87M -243M -3.61M -24.3M -9.56M -119M -9.47M -9.26M -409M
Net Debt -113K -80.39K -70.26K -64.83K -59.76K -7.74M -115K -775K -305K -3.79M -302K -295K -13.05M -231K -165K -144K -133K -122K -15.85M -236K -1.59M -624K -7.76M -618K -604K -26.72M
Logo Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine active pharmaceutical ingredients (API) and imaging contrast agents for medical radiology. It focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
Employees
-

Annual profits - Rate of surprise